Drug Profile
Research programme: diabetic neuropathies therapeutics - SciMeDent Health
Latest Information Update: 05 Sep 2013
Price :
$50
*
At a glance
- Originator Genesis Biopharma
- Class Peptidomimetics
- Mechanism of Action Peptide receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Diabetic neuropathies
Most Recent Events
- 05 Sep 2013 No development reported - Preclinical for Diabetic neuropathies in Canada (unspecified route)
- 29 Jun 2010 Preclinical trials in Diabetic neuropathies in Canada (unspecified route)